Tags

Type your tag names separated by a space and hit enter

Clinical response to CB-154 and the pituitary response to thyrotropin-releasing hormone-gonadotropin-releasing hormone in patients with galactorrhea-amenorrhea.
Fertil Steril. 1977 May; 28(5):521-5.FS

Abstract

Ten patients with galactorrhea and amenorrhea were treated with 2-bromo-alpha-ergocryptine (CB-154). All patients had normal anteroposterior and lateral x-rays of the sella turcica and normal or low gonadotropin levels. Before treatment, serum prolactin (PRL) levels were between 80 and 1575 ng/ml. Prior to initiating therapy, six patients were further evaluated by the intravenous administration of thyrotropin-releasing of a pituitary etiology in all patients. During treatment, PRL levels were measured at monthly intervals. After 1 month, serum PRL concentrations were reduced between 13% and 99%. In eight subjects there was complete cessation of galactorrhea. During treatment, nine patients resumed ovulatory menstrual cycles and three patients conceived. After discontinuing therapy, five of seven subjects had a recurrence of galactorrhea, amenorrhea, and hyperprolactinemia.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

404198

Citation

March, C M., et al. "Clinical Response to CB-154 and the Pituitary Response to Thyrotropin-releasing Hormone-gonadotropin-releasing Hormone in Patients With Galactorrhea-amenorrhea." Fertility and Sterility, vol. 28, no. 5, 1977, pp. 521-5.
March CM, Kletzky OA, Davajan V. Clinical response to CB-154 and the pituitary response to thyrotropin-releasing hormone-gonadotropin-releasing hormone in patients with galactorrhea-amenorrhea. Fertil Steril. 1977;28(5):521-5.
March, C. M., Kletzky, O. A., & Davajan, V. (1977). Clinical response to CB-154 and the pituitary response to thyrotropin-releasing hormone-gonadotropin-releasing hormone in patients with galactorrhea-amenorrhea. Fertility and Sterility, 28(5), 521-5.
March CM, Kletzky OA, Davajan V. Clinical Response to CB-154 and the Pituitary Response to Thyrotropin-releasing Hormone-gonadotropin-releasing Hormone in Patients With Galactorrhea-amenorrhea. Fertil Steril. 1977;28(5):521-5. PubMed PMID: 404198.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical response to CB-154 and the pituitary response to thyrotropin-releasing hormone-gonadotropin-releasing hormone in patients with galactorrhea-amenorrhea. AU - March,C M, AU - Kletzky,O A, AU - Davajan,V, PY - 1977/5/1/pubmed PY - 1977/5/1/medline PY - 1977/5/1/entrez KW - Alkaloids KW - Amenorrhea KW - Biology KW - Clinical Research KW - Diseases KW - Endocrine System KW - Ergot Alkaloids--therapeutic use KW - Galactorrhea KW - Hormones KW - Ingredients And Chemicals KW - Menstruation Disorders KW - Organic Chemicals KW - Physiology KW - Pituitary Hormones KW - Prolactin--analysis KW - Puerperal Disorders KW - Research Methodology SP - 521 EP - 5 JF - Fertility and sterility JO - Fertil Steril VL - 28 IS - 5 N2 - Ten patients with galactorrhea and amenorrhea were treated with 2-bromo-alpha-ergocryptine (CB-154). All patients had normal anteroposterior and lateral x-rays of the sella turcica and normal or low gonadotropin levels. Before treatment, serum prolactin (PRL) levels were between 80 and 1575 ng/ml. Prior to initiating therapy, six patients were further evaluated by the intravenous administration of thyrotropin-releasing of a pituitary etiology in all patients. During treatment, PRL levels were measured at monthly intervals. After 1 month, serum PRL concentrations were reduced between 13% and 99%. In eight subjects there was complete cessation of galactorrhea. During treatment, nine patients resumed ovulatory menstrual cycles and three patients conceived. After discontinuing therapy, five of seven subjects had a recurrence of galactorrhea, amenorrhea, and hyperprolactinemia. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/404198/Clinical_response_to_CB_154_and_the_pituitary_response_to_thyrotropin_releasing_hormone_gonadotropin_releasing_hormone_in_patients_with_galactorrhea_amenorrhea_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(16)42550-1 DB - PRIME DP - Unbound Medicine ER -